Table 1 Characteristics of included studies
Reference | Country | Disease state | Intervention | Comparator | Daily dose of colchicine (mg) | Cumulative dose of colchicine (mg) | Length of intervention | Length of follow-up for AE assessment | Total sample size | Participant characteristics |
|---|---|---|---|---|---|---|---|---|---|---|
Aran 2011 [16] | USA | Knee osteoarthritis | Colchicine, 0.5 mg twice daily | Placebo | 1 | 91 | 3 months | 3 months | 61 | Mean age 60.2 years 0% males |
Batezzati 2001 [7] | Italy | Primary biliary cirrhosis | Colchicine, 1 mg daily + ursodeoxycholic acid, 250 mg daily | Placebo + ursodeoxycholic acid, 250 mg daily | 1 | 3650 | 10 years | 10 years | 44 | Mean age 56.5 years 14% males |
Bessissow 2018 [17] | Canada | Lung resection surgery | Colchicine, 0.6 mg 3 times daily for first day, then twice daily | Placebo | 1.26 | 12.6 | 10 days | 30 days | 100 | Mean age 69 years 45% males |
Borstad 2004 [18] | USA | Chronic gouty arthritis | Colchicine, 0.6 mg twice daily | Placebo | 1.2 | 219.0 | 6 months | 6 months | 43 | Mean age 63 years 86% males |
Cohen 1991 [19] | USA | COPD in ex-cigarette smokers | Colchicine, 0.6 mg 3 times daily | Placebo | 1.8 | 25.2 | 2 weeks | 2 weeks | 16 | Mean age 65.9 years % males NR |
Cortez-Pinto 2002 [8] | Portugal | Alcoholic cirrhosis | Colchicine, 1 mg daily, 5 days/week | Placebo | 0.714 | 901.3 | 41.5 months (mean) | 41.5 months (mean) | 55 | Mean age 53.8 years 89% males |
Das 2002 [20] | India | Knee osteoarthritis | Colchicine, 0.5 mg twice daily + Piroxicam, 20 mg once daily | Placebo + Piroxicam, 20 mg once daily | 1 | 152 | 5 months | 5 months | 39 | Mean age 53 years 33% males |
Davatchi 2009 [21] | Iran | Behcet’s disease | Colchicine, 1 mg daily | Placebo | 1 | 122 | 4 months | 4 months | 282 | Mean age 32.1 years 32% males |
Deftereos 2013 [22] | Greece | Bare-metal stent restenosis in people with diabetes | Colchicine, 0.5 mg twice daily | Placebo | 1 | 182 | 6 months | 6 months | 222 | Mean age 63.6 years 65% males |
Demidowich 2019 [23] | USA | Metabolic syndrome | Colchicine, 0.6 mg twice daily | Placebo | 1.2 | 36.6 | 3 months | 3 months | 40 | Mean age 45.8 years 23% males |
Dinarello 1974 [12] | USA | Familial Mediterranean fever | Colchicine, 0.6 mg 3 times daily | Placebo | 1.8 | 602.3 | 11 months | 11 months | 11 | Mean age NR % males NR |
Fish 1997 [24] | USA | Asthma | Colchicine, 0.6 mg twice daily | Placebo | 1.2 | 50.4 | 6 weeks | 6 weeks | 71 | Mean age 34 years 48% males |
Imazio 2010 [25] | Italy | Post-periocardiotomy syndrome | Colchicine, 1 mg daily for first day then 0.5 mg daily for 1 month (<  70 kg) or 1 mg twice daily for first day then 0.5 mg twice daily for 1 month (≥70 kg) | Placebo | 0.5 to 1 | 15 to 30 | 1 month | 1 month | 360 | Mean age 66 years 66% males |
Imazio 2011 [26] | Italy | Recurrent pericarditis | Colchicine, 1 mg daily for first day then 0.5 mg daily for 1 month (< 70 kg) or 1 mg twice daily for first day then 0.5 mg twice daily for 1 month (≥ 70 kg) | Placebo | 0.5 to 1 | 91 to 182 | 6 months | 18 months | 120 | Mean age 47.6 years 53% males |
Imazio 2013 [27] | Italy | Acute pericarditis | Colchicine, 0.5 mg daily (< 70 kg) or 0.5 mg twice daily (≥ 70 kg) | Placebo | 0.5 to 1.0 | 46 to 91 | 3 months | 22 months (mean) | 240 | Mean age 52.1 years 60% males |
Imazio 2014a [28] | Italy | Post-periocardiotomy syndrome and postoperative atrial fibrillation | Colchicine, 0.5 mg daily (<  70 kg) or 0.5 mg twice daily (≥ 70 kg) | Placebo | 0.5 to 1.0 | 15 to 30 | 1 month | 3 months | 360 | Mean age 67.5 years 69% males |
Imazio 2014b [29] | Italy | Pericarditis | Colchicine, 0.5 mg daily (<  70 kg) or 0.5 mg twice daily (≥ 70 kg) | Placebo | 0.5 to 1.0 | 91 to 182 | 6 months | 18 months | 240 | Mean age 48.7 years 50% males |
Kaplan 1986 [6] | USA | Primary biliary cirrhosis | Colchicine, 0.6 mg twice daily | Placebo | 1.2 | 876.0 | 24 months | 24 months | 60 | Mean age NR 5% males |
Kershenobich 1979 [9] | Mexico | Cirrhosis | Colchicine, 1 mg daily, 5 days/week | Placebo | 0.714 | 1042.4 | 48 months | 48 months | 43 | Mean age 55.6 years 58% males |
Kershenobich 1988 [10] | Mexico | Cirrhosis | Colchicine, 1 mg daily, 5 days/week | Placebo | 0.714 | 1224.9 | 14 years (mean 4.7 years) | 14 years (mean 4.7 years) | 100 | Mean age 50.3 years 49% males |
Leung 2018 [30] | Singapore | Knee osteoarthritis | Colchicine, 0.5 mg twice daily | Placebo | 1 | 112 | 16 weeks | 16 weeks | 109 | Mean age 58.5 years 29% males |
Liebenburg 2016 [31] | South Africa | Tuberculous pericarditis | Colchicine, 1 mg daily | Placebo | 1 | 42 | 6 weeks | 6 weeks | 33 | Mean age 31 years 33% males |
Masuda 1989 [32] | Japan | Behcet’s disease | Colchicine, 1 mg daily | Cyclosporin, 10 mg/kg daily | 1 | 112 | 16 weeks | 16 weeks | 96 | Mean age NR % males NR |
McKendry 1993 [13] | Canada | Psoriatic arthritis | Colchicine, 0.6 mg daily for first week, 0.6 mg twice daily for second week, 0.6 mg 3 times daily for 6 weeks | placebo | 1.575 | 88.2 | 8 weeks | 8 weeks | 25 | Mean age 40.7 years 56% males |
Olsson 1995 [11] | Sweden | Primary sclerosing cholangitis | Colchicine, 1 mg daily | placebo | 1 | 1095 | 36 months | 36 months | 84 | Mean age 41.6 years 67% males |
Pakfetrat 2010 [33] | Iran | Recurrent aphthous stomatitis | Colchicine, 0.5 mg daily | Prednisolone, 5 mg/d daily | 0.5 | 47 | 3 months | 6 months | 34 | Mean age 31.5 years 35% males |
Paulus 1974 [34] | USA | Gout | Colchicine, 0.5 mg 3 times daily + probenecid 500 mg 3 times daily | Probenecid, 500 mg 3 times daily | 1.5 | 274 | 6 months | 6 months | 52 | Mean age 52.5 years 100% males |
Roche 1995 [14] | France | Allergic rhinitis | Colchicine, 1 mg twice daily for 3 days then once daily for 5 days | Placebo | 1.375 | 11 | 8 days | 8 days | 16 | Age range 20 to 30 years 100% males |
Schlesinger 2011 [15] | USA | Gout | Colchicine, 0.5 mg daily | Canakinumab dose ranging: single dose of 25 mg, 50 mg, 100 mg,200 mg, 300 mg or four doses at four-weekly intervals (50 mg, 50 mg, 25 mg, 25 mg) | 0.5 | 56 | 16 weeks | 24 weeks | 432 | Mean age 52.4 years 94% males |
Schnebel 1988 [35] | USA | Low back pain | Colchicine, 0.6 mg hourly for 8 h then 0.6 mg every fourth day | Placebo | 2.1 | 191.6 | 3 months | 3 months | 34 | Mean age 69.1 years 63% males |
Seideman 1987 [36] | Sweden | Psoriatic arthritis | Colchicine, 0.5 mg up to 3 times daily increased over 6 days | Placebo | 0.5 to 1.5 | 30 to 91 | 2 months | 2 months | 15 | Age range 20 to 65 years % males NR |
Tardif 2019 [37] | Canada | Myocardial Infarction | Colchicine, 0.5 mg daily | Placebo | 0.5 | 640.5 | 42 months | 42 months | 4745 | Mean age 60.6 years 81% males |
Terkeltaub 2010 [38] | USA | Gout | Colchicine, 1.2 mg followed by 0.6 mg in 1 h (low dose) or 1.2 mg followed by 0.6 mg hourly for 6 h (high dose) | Placebo | 1.8 to 4.8 | 1.8 to 4.8 | 1–6 h | 7 days | 185 | Mean age 51.5 years 95% males |
Wang 2014 [39] | China | Gout | Colchicine, 0.5 mg twice daily for 3 days then once daily | Chuanhu anti-gout mixture, 250 ml daily | 0.65 | 6.5 | 10 days | 13.4 weeks | 176 | Mean age 52.8 years 94% males |
Yurdakul 2001 [40] | Turkey | Behcet’s syndrome | Colchicine, 0.5 mg twice daily (≤50 kg), 0.5 mg alternating twice and 3 times daily (50–49 kg), 0.5 mg 3 times daily (60–75 kg), 0.5 mg alternating 3 and 3 times daily (76–84 kg), 0.5 mg 4 times daily (≥ 85 kg) | Placebo | 1 to 2 | 730 to 1460 | 24 months | 24 months | 116 | Mean age 27 years 52% males |